<DOC>
	<DOCNO>NCT01860105</DOCNO>
	<brief_summary>Following first , dose ascend study enrol 144 normal healthy volunteer ( NHVs ) , study , conduct approximately 36 NHVs , provide pertinent information determine dose-response MDCO-157 platelet aggregation inhibition P2Y12 receptor inhibition effect selection dose match antiplatelet effect 300 mg PLAVIX® ® . The study also provide additional data pharmacokinetics ( PK ) , safety tolerability single dose MDCO-157 .</brief_summary>
	<brief_title>Appraisal MDCO-157 Plavix® Pharmacokinetics Pharmacodynamics Healthy Volunteers With Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Inclusion Criteria Healthy male females 18 45 year age , inclusive . Provide write informed consent genetic test write informed consent study initiation study relate procedure Affiliated French social security system Screening baseline Fridericia 's correction ( QTcF ) interval &lt; 450 msec baseline heart rate 50 100 bpm ( inclusive ) Known suspect hypersensitivity allergy clopidogrel , Captisol , PLAVIX® , excipients Body mass index &lt; 20 &gt; 30 kg/m² Inability communicate investigator comply study related procedure , high likelihood lose follow Known suspect pregnancy lactate female Medical history , physical examination include 12lead ECG laboratory evaluation conduct screen visit result indicative disease condition might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , central nervous system ; condition may interfere absorption , distribution , metabolism excretion study drug , would place subject increase risk Tobacco product use within last 6 month prior dose Platelet count &lt; 150,000/µL A personal family history coagulation bleed disorder reasonable suspicion vascular malformation Active pathological bleeding peptic ulcer intracranial hemorrhage Positive screen Hepatitis B ( Hepatitis B Surface Antigen HBsAg ) , Hepatitis C ( Hepatitis C Antibody ) , HIV ( antiHIV 1/2 ) Received investigational drug within period 30 day 5 halflives , whichever longer , prior enrollment study Use aspirin , nonsteroidal antiinflammatory drug , CYP3A4 inhibitor ( ketoconazole ) , CYP2C19 inhibitor ( eg , omeprazole ) drug know affect platelet function coagulation within 14 day prior receive study drug ( MDCO157 oral clopidogrel ) Grapefruit within 10 day prior receive study drug ( MDCO157 PLAVIX® ) Use overthecounter medication , include herbal product , within 7 day prior administration study drug ( MDCO157 PLAVIX® ) , except 2 gram acetaminophen per day 3 day pain control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>